Chicago—Daratumumab plus bortezomib and dexamethasone (Vd) should be considered a new standard of care for relapsed or refractory multiple myeloma (MM), according to results from the Phase III CASTOR trial. The findings were presented at the 2016 annual meeting of the American Society of Clinical Oncology (abstract LBA4).
“Daratumumab-Vd significantly improved progression-free survival [PFS], time to progression and overall response rate compared with Vd alone, and this was